Title |
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
|
---|---|
Published in |
BMC Cancer, September 2012
|
DOI | 10.1186/1471-2407-12-411 |
Pubmed ID | |
Authors |
Afsar Ali Mian, Anna Metodieva, Susanne Badura, Mamduh Khateb, Nili Ruimi, Yousef Najajreh, Oliver Gerhard Ottmann, Jamal Mahajna, Martin Ruthardt |
Abstract |
Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase "escapes" the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 3% |
Canada | 1 | 3% |
Unknown | 31 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 27% |
Student > Master | 4 | 12% |
Professor | 4 | 12% |
Student > Bachelor | 4 | 12% |
Student > Ph. D. Student | 3 | 9% |
Other | 6 | 18% |
Unknown | 3 | 9% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 9 | 27% |
Medicine and Dentistry | 7 | 21% |
Chemistry | 4 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Other | 3 | 9% |
Unknown | 4 | 12% |